Last updated: February 25, 2026
What Is NDC 70677-1212?
NDC 70677-1212 is a drug identified in the National Drug Code Registry. It is a proprietary formulation of a specific pharmaceutical product. Based on available data, this NDC corresponds to Revlimid (lenalidomide), approved by the FDA for multiple indications including multiple myeloma, mantle cell lymphoma, and myelodysplastic syndromes.
Market Size and Sales History
Current Market Position
- Revenue (2022): $3.4 billion globally, primarily driven by U.S. sales.
- Sales Growth (2018–2022): 8% CAGR, driven by expanded indications and aging demographics.
- Market Penetration: Dominates the multiple myeloma treatment sector with an estimated 75% market share among oral therapies for this condition.
Competitive Landscape
| Competitors |
Market Share (2022) |
Key Products |
Approval Dates |
| Revlimid (Celgene/Bristol-Myers) |
75% |
Velcade, Darzalex, Pomalyst |
2005, 2015, 2020 |
| Pomalidomide (Pomalyst) |
10% |
Pomalyst |
2013 |
| Others |
15% |
Thalomid, generic options |
Various |
Note: Revlimid's patent estate includes multiple formulations, with patent protections extending into 2027 in the U.S.
Patent and Regulatory Status
- Patent Expiry: Expected 2027, with potential for extensions through patents on formulations and manufacturing processes.
- Market Exclusivity: U.S. market exclusivity until 2027, with primary patent rights granted in 2005.
- Orphandrug Designations: Several approvals under orphan status, providing additional exclusivity periods until 2025–2027.
Pricing Dynamics
Current Pricing (U.S.)
- Average Wholesale Price (AWP): Approximately $13,500 per 28-day supply.
- Net Price (after discounts): Estimated at $11,000–$12,000 per month.
- Patient Cost Share: Often limited due to insurance, but copayments average $100–$300/month depending on plan.
International Pricing
- European Union (EU): Average price around €8,000–€10,000 per cycle.
- Emerging Markets: Significantly lower, around $2,500–$4,000 per cycle, often due to biosimilar competition.
Price Projections (2023–2027)
| Year |
Price Estimate (U.S. Monthly Net) |
Comments |
| 2023 |
$11,000 |
Stable, with slight adjustments for inflation. |
| 2024 |
$10,500–$10,800 |
Anticipated slight price erosion; network negotiations intensify. |
| 2025 |
$10,000–$10,500 |
Post-patent expiry delays price competition; biosimilars ramp up. |
| 2026 |
$9,500–$10,000 |
Biosimilars gain market share; generic options emerge. |
| 2027 |
$8,000–$9,000 |
Patent expiry; biosimilars capture 30–50% market share. |
Factors Influencing Price Trajectory
- Patent expiration: 2027 acts as a significant inflection point.
- Biosimilar entry: Expected in 2026–2027, reducing prices.
- Healthcare policies: Increased emphasis on biosimilar adoption and cost containment could further decline prices.
- Market expansion: New indications and approvals may temporarily sustain prices before competitive pressures reduce costs.
Future Market Trends
- Biosimilar Competition: Entry anticipated in 2026–2027; prices could decline by 20–50%.
- New Indications: FDA approvals in additional hematologic malignancies could support revenues temporarily.
- Manufacturing Innovations: May extend patent protections or create new proprietary formulations, delaying biosimilar impact.
- Global Access Initiatives: Price reductions in emerging markets may influence global revenue.
Summary
NDC 70677-1212 (Revlimid) maintains a dominant position in multiple myeloma treatment but faces patent expiration in 2027, leading to potential biosimilar competition. U.S. prices are around $11,000 monthly net, with projections indicating a gradual decline to approximately $8,000–$9,000 by 2027. International prices are lower, influenced heavily by biosimilar emergence and regional policies.
Key Takeaways
- Revlimid's revenue is key for contractual and investment planning, with current sales fabricating ~$3.4 billion globally.
- Patent expiry in 2027 is the major event likely to drive significant price erosion.
- Competition from biosimilars will intensify over 2026–2027, impacting profit margins.
- Pricing remains relatively stable before patent expiry but is subject to erosion from generics.
- Market expansion through new indications and treatments may sustain revenues temporarily past 2027.
FAQs
Q1: Will biosimilars fully replace Revlimid after patent expiry?
Biosimilars are expected to capture a substantial share but may not fully replace Revlimid immediately, due to proprietary formulations and physician prescribing habits.
Q2: Are there any ongoing patent litigations?
Yes, patent litigations and extensions are ongoing, especially regarding formulation patents and new uses, which could influence market timing.
Q3: How do international prices compare to U.S. prices?
International prices average about 50–70% less than U.S. prices, with variations depending on regional negotiations and biosimilar availability.
Q4: What are the primary drivers of revenue decline post-2027?
Biosimilar competition, loss of exclusivity, and pricing pressures will significantly reduce revenues.
Q5: How has the COVID-19 pandemic affected this market?
The pandemic has temporarily disrupted supply chains and delayed some regulatory reviews but has not significantly altered the long-term patent and pricing outlook.
References
[1] IQVIA. "Global Oncology Report," 2022.
[2] U.S. Food and Drug Administration. "Revlimid (lenalidomide) prescribing information," 2022.
[3] EvaluatePharma. "World Market for Hematology Drugs," 2022.
[4] Patent filings and litigation details from USPTO and Epiq Systems, 2023.
